Introduction
At one time the process of testing new medicines was the province mainly of physicians in teaching hospitals, but this is no longer so: physicians in district hospitals and in general practice are increasingly involved because they are caring for the patients eligible for the clinical trials. In this article we review briefly the early stages in the development of a new drug, or 'new chemical entity' (NCE) , and consider especially those aspects which are important to the physician participating in that process.
Preclinical development of new medicines
After screening for pharmacological effects in both isolated tissues and whole animals, promising NCEs are subjected to a battery of acute and chronic toxicological tests in animals."2 In acute testing, increasing single doses are given to identify target organ(s) for toxicity and to assess the ratio between effective and toxic doses. In chronic testing, at least 2 species must be studied, 1 of which must be a non-rodent; the NCE must be given by the route intended to be used in man, and of the 3 dose levels tested the highest should produce some signs of toxicity. At the end ofchronic toxicity tests, histological examinations are made of all important internal organs.
Before an NCE is studied in volunteers or patients, exposure in animals should exceed the intended duration of exposure in human. In the United Kingdom animal studies lasting 14 A clinical research study which is not carried out to an adequate standard is unethical, since patients will be exposed to inconvenience, discomfort or hazard in exchange for a benefit which will be less than that which could have been achieved. GCP and GCRP are thus to be welcomed, since they encourage a uniformly high standard ofwork in the development of new pharmaceuticals.
Conclusions
The development of new medicines has generated tremendous benefits for patients in the past, and there is every reason to suppose that it will continue to do so in the future. New 
